Kyverna

Public

Emeryville, CaliforniaHealthcarewww.kyvernatx.com

Kyverna is now publicly traded

The data on this page reflects Kyverna's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Last Round

Series B

Aug 3, 2023

Total Funding Raised

$60M

Company Overview

Kyverna (NAS: KYTX) is a biopharmaceutical company specializing in the development of innovative cell therapies for patients with autoimmune diseases.

Sector

Healthcare

AI Layer

Non-AI

Keywords

CAR T-cell therapy for autoimmune diseaseautologous CD19 CAR T-cell therapycell therapy for autoimmune diseaseB-cell depleting autoimmune therapyautoimmune immune system reset therapyallogeneic CD19 CAR T-cell therapylupus nephritis cell therapymultiple sclerosis cell therapyTreg-based cell therapy platformmyasthenia gravis cell therapycell therapy for rheumatologycell therapy for neurologyengineered cell therapy development

Kyverna Comparables

Compare Kyverna with similar companies based on industry and business-model similarity.

Kyverna comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Dualyx	64%
Hinge Bio	54%
COUR Pharmaceuticals	53%

View all Comparables

Kyverna Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series B	Aug 3, 2023

View all Funding Rounds

Kyverna Investors

Notable investors and investment history

Kyverna investors
Investor	Rounds
Bain Capital Life Sciences	Series B
jVen Capital	Series B
CAM Capital	Series B
Westlake Village BioPartners	Series B
GordonMD Global Investments	Series B
LYFE Capital	Series B
Vida Ventures	Series B

View all Investors

Kyverna Filings

Explore SEC and related filing metadata, where available.

Kyverna filings preview — column headings only; records require access
Type	Date	Amount Offered	Amount Sold	Filing	Pages	Download

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Firmographic Details

HeadquartersEmeryville, California

Employee Range155

Year Founded2018

Last FundingAug 3, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?